Kirin-Amgen Inc v Hoechst Marion Roussel Ltd

Link copied
Case Copied 50 min read
HOUSE OF LORDS SESSION 2003–04
[2004] UKHL 46

on appeal from: [2002] EWCA Civ 1096

OPINIONS

OF THE LORDS OF APPEAL

FOR JUDGMENT IN THE CAUSE

Kirin-Amgen Inc and others (Appellants) v. Hoechst Marion Roussel Limited and others (Respondents) Kirin-Amgen Inc and others (Respondents) v. Hoechst Marion Roussel Limited and others (Appellants) (Conjoined Appeals) ON THURSDAY 21 OCTOBER 2004 The Appellate Committee comprised: Lord Hoffmann Lord Hope of Craighead Lord Rodger of Earlsferry Lord Walker of Gestingthorpe Lord Brown of Eaton-under-Heywood HOUSE OF LORDS OPINIONS OF THE LORDS OF APPEAL FOR JUDGMENT IN THE CAUSE Kirin-Amgen Inc and others (Appellants) v. Hoechst Marion

Roussel Limited and others (Respondents)

Kirin-Amgen Inc and others (Respondents) v. Hoechst Marion

Roussel Limited and others (Appellants)

(Conjoined Appeals)

[2004] UKHL 46

LORD HOFFMANN

My Lords,

The proceedings

1. Kirin-Amgen Inc (“Amgen”), a Californian pharmaceutical company, is the proprietor of a European patent (EP 0148605B2) relating to the production of erythropoietin (“EPO”) by recombinant DNA technology. EPO is a hormone made in the kidney which stimulates the production of red blood cells by the bone marrow. The discovery by Amgen of a method of making EPO artificially for use as a drug was a significant advance in the treatment of anaemia, particularly when associated with kidney failure. Amgen market it under the name Epogen and the patent (which will expire on 11 December 2004) has been very profitable.

2. These appeals arise out of a dispute concerning both the validity and infringement of the patent between Amgen and two other pharmaceutical companies. Transkaryotic Therapies Inc (“TKT”) is a Massachusetts corporation. It has also developed a method of making EPO, which it markets under the name Dynepo. It uses a process which it calls “gene activation” and the product been referred to in this appeal as “GA-EPO”. Hoechst Marion Roussel Ltd (“Hoechst”) is the English subsidiary of a well-known multinational pharmaceutical company which has been proposing to import GA-EPO into the United Kingdom. In three consolidated actions, Amgen claims that GA-EPO infringes the claims of the patent in suit and TKT and Hoechst claim a declaration of non-infringement and revocation of the patent. I shall for convenience refer to both Hoechst and TKT as “TKT” but it should be borne in mind that the only allegations of infringement in the United Kingdom arise out of the importation of the drug by Hoechst.

3. The science upon which recombinant DNA technology is based has been described in a number of judgments, not least in the admirable account given by Neuberger J in this case, much of which was reproduced verbatim by the Court of Appeal. I do not propose to repeat these passages but gratefully adopt them and will largely take them as read.

The race for EPO

4. The technology for manufacturing proteins (“polypeptides”) by the expression of recombinant DNA developed rapidly after the mid- 1970s. The speed of development is illustrated by the decision of your Lordships’ House in Biogen Inc v Medeva plc [1997] RPC…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Kirin-Amgen Inc v Hoechst Marion Roussel Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2004] UKHL 46
Decision Date

CaseChat Overview and Summary

Kirin-Amgen Inc, a Californian pharmaceutical company, is the proprietor of a European patent (EP 0148605B2) relating to the production of erythropoietin (EPO) by recombinant DNA technology. Amgen markets the product Epogen under the patent, which has been very profitable. Transkaryotic Therapies Inc (TKT) and Hoechst Marion Roussel Ltd (Hoechst) dispute the validity and infringement of the patent. TKT markets a similar product, GA-EPO, which uses a different process called "gene activation." The dispute involves whether TKT's product infringes Amgen's patent claims. The House of Lords, in a consolidated appeal, considered whether TKT's GA-EPO infringes Amgen's patent claims 19 and 26. The Lords concluded that the patent claims were valid but not infringed. They found claim 19 to be invalid due to insufficiency, as the patent did not adequately describe the process of producing urinary EPO (uEPO) with a specific molecular weight. Additionally, claim 26 was deemed anticipated, as TKT's process was already known. The Lords dismissed Amgen's appeal and allowed TKT's cross-appeal, revoking the patent on these grounds.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.